Andrea D. Branch, TIBS 32—Feb. 1998, pp. 45-50.* |
Jim Haseloff et al., NATURE, vol. 334, Aug. 18, 1988, pp. 585-591.* |
Usman et al., “Chemical modification of hammerhead ribozymes: activity and nuclease resistance,” Nucleic Acids Syposium Series 31:163-164 (1994). |
International Search Report, PCT/US96/17480. |
Aiello et al., “Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders” New Engl. J. Med. 331:1480-1487 (1994). |
Berkman et al., “Expression of the Vascular Permeability Factor/Vascular Endothelial Growth Factor Gene in Central Nervous System Neoplasms” J. Clini. Invest. 91:153-159 (1993). |
Burger et al., “Expermental Corneal Neovascularization: Biomicroscopic, Angiographic, and Morphologic Correlation” Cornea 4:35-41 (1985). |
Detmar et al., “Overexpression of Vascular Permeability Factor/Vascular Endothelial Growth Factor and Its Receptors in Psoriasis” J. Exp. Med. 180:1141-1146 (1994). |
Fava et al., “Vascular Permeability Factor/Endothelial Growth Factor (VPF/VEGF): Accumulation and Expression in Human Synovial Fluids and Rheumatoid Synovial Tissue” J. Exp. Med. 180:341-346 (1994). |
Ferrara, “Vascular Endothelial Growth Factor” Trends Cardiovas, Med. 3:244-250 (1993). |
Folkman, “Tumor Angiogenesis” Adv. Cancer, Res. 43:175-203 (1985). |
Fong, et al., “Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium” Nature 376:66-70 (1995). |
Gitay-Goren et al., “The Binding of Vascular Endothelial Growth Factor to Its Receptors Is Dependent on Cell Surface-associated Heparin-like Molecules” J. Biol. Chem. 267:6093-6098 (1992). |
Grant et al., “Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor” Diabetologia 36:282-291 (1993). |
Koch et al., “Vascualr Endothelial Growth Factor” J. Immunol. 152:4149-4155 (1994). |
Lepri, et al., “Effect of Low Molecular Weight Heparan Sulphate on Angiogenesis in the Rat Cornea After Chemical Cauterization” J. Ocular Pharmacol. 10:273-280 (1994). |
Matthews et al., “A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit” Prior. Natl. Acad. Sci., USA, 88:9026-9030 (1991). |
Millauer et al., “Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant” Nature 367:576-579 (1994). |
Miller et al., “Vascular Endothelial Growth Factor/Vascular Permeability Factor Is Temporally and Spatially Correlated with Ocular Angiogenesis in a Primate Model” Am. J. Pathol. 145:574-584 (1994). |
Neufeld et al., “Vascular Endothelial Growth Factor and its Receptors” Prog. Growth Factor Res. 5:89-97 (1994). |
O'Reilly et al., “Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma” Cell 79:315-328 (1994). |
Ormerod et al., “Effects of Altering the Eicosanoid Precursor Pool on Neovascularization and Inflammation in the Alkali-burned Rabbit Cornea” Am. J. Pathol. 137:1243-1252 (1990). |
Pandey et al., “Role of B61, the Ligand for the Eck Receptor Tyrosine Kinase, in TNF-α—Induced Angiogenesis” Science 268:567-569 (1995). |
Passaniti et al., “Methods in Labortory Investigation, A simple, Quantitative Method of Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor” Lab. Invest. 67: 519-528 (1992). |
Pierce et al., “Vascular endothelial growth factor/vascular permeability factor expression ina mouse model of retinal neovascularization” Proc. Natl. Acad. SCi. USA. 92:905-909 (1995). |
Plouët et al., “Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells” EMBO J. 8:3801-3806 (1989). |
Senger et al., “Vascular permeability factor (VPF, VEGF) in tumor biology” Cancer and Metas. Rev. 12:303-324 (1993). |
Shalaby et al., “Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice” Nature 376:62-66 (1995). |
Shibuya et al., “Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family” Oncogene 5:519-524 (1990). |
Shweiki et al, “Patterns of Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Mice Suggest a Role in Hormonally Regulated Angiogenesis” J. Clin. Invest. 91:2235-2243 (1993). |
Takahashi et al., “Markedly Increased Amounts of Messenger RNAs for Vascular Endothelial Growth Factor and Placenta Growth Factor in Renal Cell Carcinoma Associated with Angiogenesis” Cancer Res. 54: 4233-4237 (1994). |
Takeshita et al., “Therapeutic Angiogenesis, A single Intraarterial Bolus of Vascular Endothelial Growth Factor Augments Revascularization in a Rabbit Ischemic Hind Limb Model” J. Clin. Invest. 93:662-670 (1994). |
Terman et al., “Identification of a new endothelial cell growth factor receptor tyrosine kinase” Oncogene 6:1677-1683 (1991). |
Usman et al., “Exploiting the chemical synthesis of RNA,” TIBS 17:334-339 (1992). |
Vaisman et al., “Characterization of the Receptors of Vascular Endothelial Growth Factor” J. Bio. Chem. 265:19461-19466 (1990). |
Zieche et al., “Angiogenesis Can Be Stimulated or Repressed In vivo by a Change in GM3:GD3 Ganglioside Ratio” Lab. Invest. 67:711-715 (1992). |
Beigelman et al., “Chemical Modification of Hammerhead Ribozymes,” J. Biol. Chem. 270:25702-25708 (1995). |
Carter, “Adeno-Associated Virus Vectors,” Curr. Opi. Biotech. 3:533-539 (1992). |
Chen et al., “Multitarget-Ribozyme Directed To Cleave at up to Nine Highly Conserved HIV-1 env RNA Regions Inhibits HIV-1 Replication Potential Effectiveness Against Most Presently Sequenced HIV-1 Isolates,” Nucleic Acids Research 20:4581-4589 (1992). |
Chowrira et al., “Extensive Phosphorotioate Substitution Yields Highly Active and Nuclease-Resistant Hairpin Ribozymes,” Nucleic Acids Res., 20:2835-2840 (1992). |
Chowrira et al., “In Vitro and in Vivo Comparison of Hammerhead, Hairpin, and Hepatitis Delta Virus Self-Processing Ribozyme Cassettes,” J. Biol. Chem. 269:25856-25864 (1994). |
Collins et al., “Reaction Conditions and Kinetics of Self-Cleavage of a Ribozyme Derived From Neurospora VS RNA,” Biochemisry 32:2795-2799 (1993). |
Dropulic et al., “Functional Characterization of a U5 Ribozyme: Intracellular Suppression of Human Immunodeficiency Virus Type I Expression,” Journal of Virology, 66:1432-1441 (1992). |
Duval-Valentin et al., “Specific inhibition of transcription by triple helix-forming oligonucletides,” Proc. Natl. Acad. Sci. USA 89:504 (1992). |
Egholm et al., “PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules,” Nature 365:566-568 (1993). |
Elroy-Stein et al., “Cytoplasmic Expression System Based on Constitutive Synthesis of Bacteriophage T7 RNA Polymerase in Mammalian Cells,” Proc. Natl. Acad. Sci. USA 87:6743-6747 (1990). |
Folkman et al., “Angiogenesis,” J. Biol. Chem. 267:10931-10934 (1992). |
Folkman, “What is the Evidence that Tumors are Angiogenesis Dependent?” Journal of the National Cancer Institute 82:4-6 (1990). |
Gao et al., “Cytoplasmic Expression of a Reporter Gene by Co-Delivery of T7 RNA Polymerase and T7 Promoter Sequence with Cationic Liposomes,” Nucleic Acids Res 21:2867-2872 (1993). |
Guerrier-Tekada et al., “The RNA Moiety of Ribonuclease P Is the Catalytic Subunit of the Enzyme,” Cell 35:849-857 (1983). |
Hampel et al., “Hairpin' Catalytic RNA Model: Evidence for Helices and Sequence Requirement for Substrate RNA,” Nucleic Acids Res. 18:299 (1990). |
Hampel et al., “RNA Catalytic Properties of the Mimimum a(−)sTRSV Sequence,” Biochemistry 28:4929-4399 (1989). |
Izant et al., “Constitutive and Conditional Suppression of Exogenous and Endogeneous Genes by Anti-Sense RNA,” Science 229:345-352 (1985). |
Jaeger et al., “Improved Predictions of Secondary Structures for RNA,” Proc. Natl. Acad. Sci. USA, 86:7706-7710 (1989). |
Jellinek et al., “Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor,” Biochemistry 33:10450-10456 (1994). |
Kashani-Sabet et al., “Reversal of the Malignant Phenotype by an Anti ras Ribozyme,” Antisense Research and Development., 2:3-15 (1992). |
Kim et al., “Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo,” Nature 362:841-844 (1993). |
L'Huillier et al., “Cytoplasmic Delivery of Ribozymes Leads to Efficient Reduction in α-Lactalbumin mRNA Levels in C1271 Mouse,” EMBO J. 11:4411-4418 (1992). |
Lieber et al., “Stable High-Level Gene Expression in Mammalian Cells by T7 Phage RNA Polymerase,” Methods Enzymol., 217:47-66 (1993). |
Lisziewics et al., “Inhibition of Human Immunodeficiency Virus Type 1 Replication by Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy for Gene Therapy in AIDS,” Proc. Natl. Acad. Sci. USA 90:8000-8004 (1993). |
McGarry et al., “Inhibition of heat shock protein synthesis by heat-inducible antisense RNA,” Proc. Natl. Acad. Sci. USA 83:399-403 (1986). |
Millauer et al., “High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis,” Cell 72:835-846 (1993). |
Milligan et al., “Synthesis of Small RNAs Using T7 RNA Polymerase,” Methods Enzymol, 180:51-62 (1989). |
Ohkawa et al., “Activities of HIV-RNA Targeted Ribozymes Transcribed From a ‘Shot-Gun’ Type Ribozyme-trimming Plasmid,” Nucleic Acids Symp. Serv., 27:15-16 (1992). |
Ojwang et al., “Inhibition of Human Immunodeficiency Virus Type 1 Expression by a Hairpin Ribozyme,” Proc. N atl. Acad. Sci. USA 89:10802-10806 (1992). |
Perrault et al., “Mixed Deoxyribo- and Ribo-Oligonucleotides with Catalytic Activity,” Nature 344:565-567 (1990). |
Perrotta et al., “Cleavage of Oligoribonucleotides by a Rybozyme Derived from the Hepatitis δ Virus RNA Sequence,” Biochemistry 31:16-21 (1992). |
Pieken et al., “Kinetic Characterication of Ribonuclease-Resistant 2′-Modified Hammerhead Ribozymes,” Science 253:314-317 (1991). |
Plate et al., “Vascular endothelial growth factor is potential tumor angiogenesis factor in human gilomas in vivo,” Nature 359:845-848 (1992). |
Rossi et al., “Ribozymes as Anti-HIV-1 Therapeutic Agents: Principles, Applications, and Problems,” Aids Research and Human Retroviruses 8:183-189 (1992). |
Sarver et al., “Ribozymes as Potential Anti-HIV-1 Therapeutic Agents,” Science 247:1222-1225 (1990). |
Saville et al., “A Site-Specific Self-Cleavage Reaction Performed by a Novel RNA In Neurospora Mitochondria,” Cell 61:685-696 (1990). |
Saville et al.,Proc. Natl. Acad. Sci. USA 88:8826-8830 (1991). |
Scanlon et al., Proc. Natl. Acad. Sci. USA 88:10591-10595 (1991). |
Scaringe et al., “Chemical synthesis of biologically active oligoribonucleotides using β-cyanoethyl protected ribonucleoside phosphoramidites,” Nucleic Acids Res. 18:5433-5441 (1990). |
Stein et al., “Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?” Science 261:1004-1288 (1993). |
Taira et al., “Construction of a novel RNA-transcript-trimming plasmid which can be used both in vitro in plce of run-off and (G)-free transcriptions and in vivo as multi-sequences transcription vectors,” Nucleic Acids Res., 19:5125-5130 (1991). |
Thompson et al., “Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter,” Nucleic Acids Res. 23:2259-2268 (1995). |
Torrence et al., “Targeting RNA for degradation with a (2′-5′) oligoadenylate-antisense chimera,” Proc. Natl. Acad. Sci. USA 90:1300-1304 (1993). |
Usman et al., “Automated Chemical Synthesis of Long Oligoriibonucleotides Using 2′-O-Silylated Ribonycleoside 3′-O-Phosphoramidites on a Controlled-Pore Glass Support: Synthesis of a 43-Nucleotide Sequence Similar to the 3′-Half Molecule of a Escherichia coli Formylmethoionine tRNA,” J. Am. Chem. Soc., 109:7845-7854 (1987). |
Usman et al., “Chemical modification of hammerhead Ribozymes: activity and nuclease resistance,” Nucleic Acids Symp. Ser. 31:163-164 (1994). |
Usman et al., “Exploiting the chemical synthesis of RNA” TIBS. 17:334-339 (1992). |
Ventura et al., “Activation of HIV-Specific Ribozyme Activity by Self-Cleavage” Nucleic Acids Res., 21:3249-3255 (1993). |
Weerasinghe et al., “Resistance to Human Immunodeficiency Virus Type 1 (HIV-1) Infection in Human CD4+ Lymphocyte-Derived Cell Lines Conferred by Using Retroviral Vectors Expressing an HIV-1 RNA-Specific Ribozyme,” Journal of VIrology 65:5531-5534 (1991). |
Wincott et al., “Synthesis, deprotection, analysis and purification of RNA and ribozymes,” Nucleic Acids Research 23:2677-2684 (1995). |
Yu et al., “A Hairpin Ribozyme Inhibits Expression of Diverse Strains of Human Immunodeficiency Virus Type 1,” Proc. Natl. Acad. Sci. USA 90:6340-6344 (1993). |
Zabner et al., “Adenovirus-Mediated Gene Transfer Transiently Corrects the Chloride Transport Defect in Nasal Epithelia of Patients with Cystic Fibrosis,” Cell 75:207-216 (1993). |
Zhou et al., “Synthesis of Functional mRNA in Mammalian Cells by Bacteriophage T3 RNA Polymerase,” Mol. Cell. Biol., 10:4529-4537 (1990). |
International Search Report, PCT/US02/17674, filed May 29, 2002. |
Parry et al. 1999. “Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA,” Nucleic Acid Res. 27:2569-77. |